大发快三官网pk10_British new lung cancer drug wins approval in China

  • 时间:
  • 浏览:2
  • 来源:台湾新闻网_台湾主流媒体_台湾门户网站

Th大发快三官网pk10大发快三官网pk10e London stock market listed company AstraZeneca Monday anno大发快三官网pk10unced that the China Food and Drug Administration (CFDA) has granted marketing authorization for its lung cancer pill Tagrisso in China.

Tagrisso (osimertinib) is designed for the treatment of adult patients with certain genetic mutations, which is the first AstraZeneca medicine approved under the CFDA's Priority Review pathway, using an accelerated timeline for an innovative medicine.

Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "This is an important step forward for Tagrisso and a significant opportunity to bring a breakthrough medicine to patients with NSCLC (non-small cell lung cancer) in China, where EGFR (epidermal growth factor receptor) rates are some of the highest in the world."

According to the company, the rapid review and approval signal the urgent need for new, targeted treatments with the potential to address specific types of cancer with high incidence rate and significant unmet medical need in China.

猜你喜欢

大发快三官网pk10_British new lung cancer drug wins approval in China

Th大发快三官网pk10大发快三官网pk10eLondonstockmarketlistedcompanyAstraZenecaMondayanno大发快三官网pk10unce

2019-11-22

大发快三官网pk10_Chinese fintech companies make claims on the future

A大发快三官网pk10sZan大发快三官网pk10eWangseesit,大发快三官网pk10china'syoung"areconfidentabouttheirfuture

2019-11-10

大发快三官网pk10_智能家居的安全系数高吗?

智能音响、智能冰箱、智能门锁等等,哪些地方地方智能家居产品很多 地进入家庭,消费者似乎假如有一天轻松地通过手机或语音识别发出指令,就能享受方便快捷的自动服务。但德国数字法学会

2019-10-25